HeartSciences Granted U.S. Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence

Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), a medical technology company focused on applying innovative AI-based technology to an ECG to significantly expand and improve an ECG's clinical usefulness by detecting cardiac dysfunction, today announced that it has been granted a patent from the United States Patent and Trademark Office for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods.

Diastolic dysfunction (impaired cardiac relaxation) is an important indicator of overall heart health, as it is impaired by all of the common pathological processes of heart disease and is a sensitive indicator of cardiovascular dysfunction. Diastolic dysfunction is recognized as one of the earliest signs of heart disease, with typical onset occurring when a patient is still asymptomatic.

"The ECG is a ubiquitous, relatively low-cost, simple and quick test that can be performed in a wide range of clinical settings by a non-specialist clinician or clinical aide. One of the most significant needs in healthcare is the ability to detect cardiac dysfunction early. Adding diagnostic information related to cardiac dysfunction to an ECG would not only make it a far more valuable cardiac screening tool, but also addresses a significant unmet need in the market with an estimated 100 million plus ECG tests performed annually in the USA alone," said Andrew Simpson, CEO of HeartSciences.

The Company to date has been granted eight patents in the U.S. (including the one announced in this press release), bringing its total granted patents, including international, to eighteen as of the date of this press release.